The impact of adjuvant therapy on survival in patients with FIGO Stage IB Grade 3 endometrial cancer

摘要

Purpose of Investigation: To examine the patterns of care, predictors, and impact of adjuvant therapy on survival in patients with Stage IB Grade 3 endometrial cancer. Materials and Methods: The Surveillance, Epidemiology, and End Results (SEER)-Medicare database was used to identify women 65 years or older diagnosed with Stage IB Grade 3 endometrial cancer from 1991 through 2007. Results: A total of 624 women were included. Adjuvant external beam radiation therapy (EBRT) was administered in 54% of the patients, while 22% received vaginal brachytherapy (VBT), and 7% received chemotherapy. In Cox-proportional hazards regression models, neither EBRT (HR: 0.94; 95% CI; 0.71-1.22), nor VBT (HR: 0.84; 95% CI: 0.60-1.17), or chemotherapy (HR: 1.30: 95% CI; 0.64-2.66) was associated with reduced mortality in patients with Stage IB Grade 3 endometrial cancer. Conclusion: Although commonly used; neither adjuvant radiation nor chemotherapy significantly improves survival in patients with Stage IB Grade 3 endometrial cancer.